In pancreatic cancers, the inactivation of Smad4 significantly correlates with poor prognosis in patients with surgically resected adenocarcinoma of the pancreas (Blackford et al., 2009). This evidence concerns the gene SMAD4 and familial pancreatic carcinoma.